Linked Life Data

7529606

Source:http://linkedlifedata.com/resource/pubmed/id/7529606

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1995-2-15
pubmed:abstractText
The use of the recombinant hematopoietic growth factors G-CSF and GM-CSF have shortened the period of neutropenia, or avoided this problem, in many cancer patients who have received cytotoxic therapy. Although these benefits have been particularly striking in the autologous bone marrow and/or autologous peripheral blood progenitor cell transplant setting, most data suggest that the use of G-CSF and GM-CSF only marginally enhance recovery of the neutrophil count when administered after allogeneic bone marrow infusion. Furthermore, in the allograft setting these expensive agents have not provided benefit in the form of enhanced platelet count recovery, lessening the incidence of graft-versus-host disease, or improvement in overall survival. These data do not justify routine widespread use of G-CSF and GM-CSF and suggest that these agents should be reserved for patients who experience delay in engraftment after allogeneic bone marrow infusion. Administration of erythropoietin, on the other hand, may reduce the need for homologous red blood cell transfusions, and may increase the safety margin for both the allogeneic bone marrow recipient and as well as the donor. Recombinant hematopoietic growth factors targetted specifically to enhance platelet recovery after transplantation (such as interleukin-3, interleukin-6, and interleukin-11) have shown promise after autotransplantation and after conventional dose chemotherapy, and likely will be evaluated in the allogeneic transplant patient.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0268-960X
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
169-78
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:7529606-Bone Marrow Transplantation, pubmed-meshheading:7529606-Clinical Trials as Topic, pubmed-meshheading:7529606-Erythropoietin, pubmed-meshheading:7529606-Graft Survival, pubmed-meshheading:7529606-Graft vs Host Disease, pubmed-meshheading:7529606-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:7529606-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:7529606-Hematopoiesis, pubmed-meshheading:7529606-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:7529606-Humans, pubmed-meshheading:7529606-Lymphocyte Depletion, pubmed-meshheading:7529606-Macrophage Colony-Stimulating Factor, pubmed-meshheading:7529606-Neoplasms, pubmed-meshheading:7529606-Neutropenia, pubmed-meshheading:7529606-Recombinant Proteins, pubmed-meshheading:7529606-Transplantation, Homologous, pubmed-meshheading:7529606-Treatment Outcome
pubmed:year
1994
pubmed:articleTitle
Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation.
pubmed:affiliation
Department of Medicine, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Ohio.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review